🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 115 of 857 · Phase 3 first, then by program name

  1. NKTR-102

    Nektar Therapeutics UK Limited

    Metastasis

    phase 3 small molecule completed

    1 trial

  2. NKTR-118

    AstraZeneca

    Opioid-Induced Constipation

    phase 3 small molecule terminated

    1 trial

  3. NKTR-181 BID tablets

    Nektar Therapeutics UK Limited

    Low Back Pain

    phase 3 small molecule completed

    2 trials

  4. NKTR-214

    Nektar Therapeutics UK Limited

    Melanoma

    phase 3 mab completed

    1 trial

  5. NKTR-214

    Bristol-Myers Squibb

    Melanoma

    phase 3 mab completed

    1 trial

  6. NKTR-255 at 1.5 µg/kg

    Nektar Therapeutics UK Limited

    Non-Hodgkin Lymphoma

    phase 3 small molecule terminated

    1 trial

  7. NMRA-335140

    Neumora Therapeutics

    Major Depressive Disorder

    phase 3 small molecule active

    5 trials

  8. NMRA-335140

    Neumora Therapeutics

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  9. NNC0487-0111

    Novo Nordisk A/S

    Obesity

    phase 3 small molecule active

    1 trial

  10. NNC0487-0111 B 10142, NNC0487-0111 B 10141, Placebo, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10143, NNC0487-0111 B 10144

    NovoThirteen

    Overweight or obesity, and knee osteoarthritis

    phase 3 small molecule active

    1 trial

  11. NNC0487-0111 B 10142, NNC0487-0111 B 10143, NNC0487-0111 B 10141, NNC0487-0111 B 10145, Placebo, NNC0487-0111 B 10146, NNC0487-0111 B 10144

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  12. NNC0487-0111 B 10142, Placebo (NNC0487-0111), NNC0487-0111 B 10143, NNC0487-0111 B 10146, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10141

    NovoThirteen

    HFpEF or HFmrEF and obesity

    phase 3 small molecule active

    1 trial

  13. NNC0487-0111 B 10143, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10142, NNC0487-0111 B 10146, Placebo, NNC0487-0111 B 10141

    NovoThirteen

    Overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure

    phase 3 small molecule active

    1 trial

  14. NNC0487-0111 B 10146, NNC0487-0111 B 10143, NNC0487-0111 B 10142, NNC0487-0111 B 10145, Placebo, NNC0487-0111 B 10144, NNC0487-0111 B 10141

    NovoThirteen

    Overweight or obesity, and obstructive sleep apnoea treated with positive airway preassure (PAP)

    phase 3 small molecule active

    1 trial

  15. NNC0487-0111 B 10146, NNC0487-0111 B 10145, Placebo, NNC0487-0111 B 10143, NNC0487-0111 B 10144, NNC0487-0111 B 10142, NNC0487-0111 B 10141

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  16. NNC0487-0111 B 10146, Placebo, NNC0487-0111 B 10141, NNC0487-0111 B 10142, NNC0487-0111 B 10143, NNC0487-0111 B 10145, NNC0487-0111 B 10144

    NovoThirteen

    Overweight or obesity, and type 2 diabetes

    phase 3 small molecule active

    1 trial

  17. NORADRENALINA TARTRATO MONICO 2 mg/ml Concentrato per soluzione per infusione

    Lacuna Pharma Pty Ltd

    criticall illness

    phase 3 small molecule active

    1 trial

  18. NP101

    Teva Pharma GmbH

    Migraine Disorders

    phase 3 small molecule completed

    2 trials

  19. NP101 Sumatriptan Iontophoretic Transdermal Patch

    Teva Pharma GmbH

    Migraine Disorders

    phase 3 small molecule completed

    2 trials

  20. NPC-11 for intravenous or oral administration.

    Belpharma s.a.

    Apnea of Prematurity

    phase 3 small molecule completed

    1 trial

  21. NPSP558

    Takeda

    Hypoparathyroidism

    phase 3 small molecule completed

    3 trials

  22. NTLA-2001

    Regeneron UK Limited

    Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

    phase 3 mab active

    1 trial

  23. NUBEQA 300 mg film-coated tablets, Placebo to BAY1841788 film-coated tablet 300 mg

    Ningbo Cancer Hospital

    Localised Very High-Risk Cancer of the Prostate

    phase 3 small molecule active

    1 trial

  24. NUC01, Placebo to NUC01

    Dr. Falk Pharma GmbH

    primary sclerosing cholangitis (PSC)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources